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Midsagittal view of the pituitary gland in relation to the bony structures 
and the brain (adapted from Netter)
Figure 2
View on the caudal side of the brain, showing the pituitary gland 




A multidisciplinary approach is currently preferred in diagnosis and treatment deci-
sion-making in pituitary adenoma patients. In the multidisciplinary neuro-endocrine 
meetings of the University Medical Center Groningen, the clinical benefits as opposed to 
potential side effects of radiation therapy, as reported by other centres, were frequently 
debated, resulting in suboptimal consistency in our approach to this patient category. 
In order to increase our understanding of the clinical consequences of (post-operative) 
radiation therapy as compared to no radiation therapy, it was decided to evaluate the 
outcome of this treatment among pituitary adenoma patients treated in our institution 
during the past decades. The single-centre cohort studies described in this thesis are 
aimed to improve evidence-based decision-making in pituitary adenoma patients.
Pituitary Anatomy
The pituitary gland is a bean-shaped small organ, located in the sellar fossa, in the 
centre of the skull base at the base of the brain. The word “pituitaria” is derived from 
the Greek word “ptuo”, which means “spew” and the Latin word “ptuita” (mucus). The 
normal size of the gland is approximately 10 mm in length, 5 to 10 mm in height and 10 
to 15 mm in width (Figure 1 and Figure 2). The normal weight is 500-600 mg. This organ 
plays a central role in hormone regulation; it integrates hormonal signals that control 
adrenal, thyroid, reproductive, growth, and metabolic functions. 
The pituitary gland is divided in the anterior and the posterior lobe, the so-called 
adeno- and neurohypophysis. The anterior lobe contains 75 percent of the pituitary gland, 
in which different hormones are produced. The most important are: growth hormone 
(GH), prolactin (Pr), adrenocorticotrophic hormone (ACTH), thyrotropin (TSH), luteinising 
hormone (LH) and follicle-stimulating hormone (FSH), produced by at least 5 different cell-
types. These different cell types are clustered and have their own position in the pituitary 
gland; ACTH and TSH in the centre of the anterior pituitary lobe and PR and GH at both 
lateral sides. The posterior lobe is a storage for anti-diuretic hormone (ADH) and oxytocin, 
produced in the hypothalamus. The pituitary gland has a connection with the hypothala-
mus via the pituitary stalk and portal system. Neighbouring structures are the optic chi-
asm and optic nerves antero-superior, the sphenoid sinus antero-inferior, the cavernous 
sinus and the cranial nerves III, IV, V and VI at both lateral sides and dorsal the clivus. 
Pituitary adenomas
Pituitary adenomas originate only in the anterior lobe. In the vast majority of cases, 
they are monoclonal and are characterised by complete disruption of the reticulin fi-
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bre network in contrast to pituitary hyperplasia1. These adenomas are benign lesions, 
comprising 10-15% of all intracranial tumours2,3. Pituitary adenomas can be divided 
in secreting and non-secreting tumours. Secreting tumours produce an excess of pi-
tuitary hormones with each its own syndrome: Pr (Prolactinoma), GH (Acromegaly, 
gigantism), ACTH (Cushing’s disease), TSH (Thyrotrophinoma), and LH/FSH (Gonado-
trophinoma). Although almost all pituitary adenomas are classified as benign, many of 
these lesions are locally invasive and cause major morbidity and mortality. The patho-
genetic mechanism in pituitary tumour genesis is complex and enigmatic4.
Incidence en prevalence
The incidence for all pituitary adenomas is estimated at 80 million persons per year. 
An increase in the incidence is reported in the time period 1958-1991 in Sweden3. The 
peak incidence occurs in the fourth to the sixth decade of life5. Incidence and prevalence 
numbers for the Netherlands are not available.
In a systematic review, the prevalence of pituitary adenomas in the general popu-
lation has been estimated at 16.7% (14.4% in autopsy studies and 22.5% in radiologic 
studies). The prevalence of macroadenomas (>1 cm) has been estimated at 0.16-0.2%6. 
These figures contradict the conventional view of pituitary tumours as rare; pituitary 
adenomas are in fact common in the general population. 
Approximately 25% of all pituitary adenomas are clinically non-functioning/ 
non-secreting (NFA). The incidence is estimated at 10 per million persons per year. In 
Belgium, the prevalence of clinically significant non-secreting pituitary adenomas was 
138/1.000.000. The male to female ratio is estimated at: 3 : 28.
The incidence of prolactin producing pituitary adenomas (PR) is estimated at 
6-10 per million persons per year and the prevalence at 60-100 per million9. A female 
preponderance is observed of 20 to 1 in microadenomas; in macroadenomas female to 
male ratio is equal.
The incidence of growth-hormone producing pituitary adenomas (GH) is esti-
mated at 4-6 per million persons per year and the prevalence at 40-60 per million9,10. The 
incidence of ACTH producing pituitary adenomas (ACTH) is estimated at 2-3 per million 
persons per year and the prevalence at 20-30 per million9.
TSH (Thyrotrophinoma) and LH/FSH (Gonadotrophinoma) are rare pituitary ade-
nomas9. Because of their rarity these tumours are not discussed in detail.
Clinical symptoms
NFAs, frequently macroadenomas, usually present with signs as a result of local mass 
effect and extension outside the sella turcica. Symptoms are bitemporal hemianopsia, 
decreased visual acuity, ophthalmoplegia and signs and symptoms as a consequence of 
hormonal insufficiency. Loss of vision due to NFA is caused by compression of the optic 
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system and results in visual field defects in 85% and in complete blindness in 2% of NFA-
patients8. Ophthalmoplegia is caused by invasion of the tumour in the cavernous sinus, 
compressing the third, fourth and sixth cranial nerve.
Hypopituitarism due to pituitary adenoma is caused directly by destruction or 
compression of normal pituitary tissue or indirectly due to compression of the pitu-
itary stalk or of the portal circulation with focal necrosis of normal pituitary tissue as 
a result11. The prevalence of hypopituitarism is largely restricted to macroadenomas12. 
Features of pituitary insufficiency include decreased libido and/or erectile dysfunction 
in men, irregular menses or amenorrhea in premenopausal women, and fatigue (thyroid 
hormone, cortisol, GH deficiency or deficiencies).
Secreting pituitary adenomas are in general smaller than NFA at the time of diag-
nosis, because their symptoms are based on excessive hormone production.
Prolactinoma with its hypersecretion of prolactin in women can result in irregu-
lar menses or amenorrhea, galactorrhea and loss of libido. In men, loss of libido and 
impotence is observed.
With GH excess, leading to the syndrome of acromegaly, features develop insidi-
ously over decades, often resulting in a delay of 5 to 10 years in diagnosis after the esti-
mated onset of symptoms. Symptoms are enlargement of the acra (facial bones, hands 
and feet), paresthesias, excessive sweating, arthropathy, headache, tiredness, and sleep 
apnoea.
Cushing’s disease is caused by ACTH overproduction and characterized by weight 
gain, centripetal fat distribution, fatigue, memory loss, irritability, depression, muscle 
weakness, osteoporosis and purple striae.
Mortality
Overall mortality is reported to be higher in pituitary adenoma patients in comparison 
with the normal population, primarily as a result of cardiovascular and cerebrovascular 
disease3.
In a large cohort of mainly non-functioning pituitary adenomas of the Royal 
Marsden Hospital, the overall age adjusted relative risk (RR) of death was 1.76 in com-
parison with the normal population13. The few deaths from progressive pituitary ade-
noma and from second brain tumours accounted for only a small excess mortality. An 
increased mortality was reported due to cerebrovascular accidents. In the pituitary ade-
noma cohort of 334 patients, treated between 1962 and 1986, 128 deaths were observed 
versus 80.9 expected (RR of death: 1.58 (95% CI: 1.32 - 1.9). Of these 128 deaths, 33 (26%) 
were due to cerebrovascular deaths compared with 8.04 expected (RR 4.11: 95%CI: 2.84 - 
5.75). Three of the 33 cerebrovascular deaths were due to subarachnoidal haemorrhage, 
compared to 0.54 expected deaths (RR 5.51: 95%CI: 1.14 -16.09). Any relationship with 
hypopituitarism, extent of surgery or radiation therapy could not be found.
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The Danish registry however reported no increased mortality due to cardiovascu-
lar and cerebrovascular disease. In this study, type of surgery and radiation therapy were 
not identified as risk factors, while female sex was a risk factor8. Moreover, no increased 
mortality due to malignant disease was reported in all kinds of pituitary adenoma8.
Other groups however, report an increased mortality in incompletely controlled 
acromegaly patients in comparison with the general population due to cardiovascular 
and malignant disease14,15.
Patients with untreated Cushing’s syndrome have excess mortality 16.
Treatment modalities
Active surveillance
An incidentaloma, most frequently a microadenoma (<1 cm), is diagnosed in about 10 
percent of healthy persons on MRI, made for other reasons17,18.
Patients with an incidentaloma have a slightly increased risk of morbidity and 
mortality, which implies a benefit of early diagnosis19. Therefore a conservative approach 
with repeat scanning done at yearly intervals is suggested17.
Medication
Non-functioning pituitary adenomas in general do not respond to medical treatment20. 
Patients with a prolactinoma have a treatment response of 95% on dopamine-agonists 
and therefore medical treatment is the first choice.
Acromegalic patients respond in 65% of the cases on somatostatin analogues and 
in more than 90% on Pegvisomant, a GH-receptor antagonist. Side-effects of somatosta-
tin analogues are diarrhea in 11%, flatulence in 8%, hair loss in 8%, episodically abdomi-
nal cramps in 3%, and gallbladder abnormalities in <10% of the patients. Pegvisomant is 
expensive and in general does not result in tumour shrinkage21 and may even result in 
tumour growth22.
In case of Cushing’s disease, medication is directed at decreasing adrenal steroid 
secretion (e.g. ketoconazole, metyrapone, aminoglutethimide). These drugs frequently lose 
effectiveness when the decrease in cortisol secretion results in enhanced ACTH secretion, 
leading to escape from the competitive blockade on adrenal steroid biosynthesis. Long-
term ketoconazole is not recommended because of the risk of liver function impairment. 
Mortality due to medication has not been reported.
Surgery
Surgery was first used by Horsley in 1889 but was refined by Cushing23. The treatment of 
choice is either transsphenoidal or transcranial neurosurgical adenomectomy, aiming 
at complete tumour removal or decompression of surrounding structures. The trans-
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sphenoidal approach usually allows for potential resection of a sellar tumour without 
entering the subarachnoid space, thereby minimizing the risk of complications such as 
cerebrospinal fluid leakage or meningitis. Complete surgical removal is often impossi-
ble, because of the invasive character of microadenomas and larger pituitary adenomas, 
with infiltration of the neighbouring structures such as arachnoid membrane, dura, 
sinus cavernosus and the skull base24,25. 
The neurosurgeon’s conclusions on complete resection during operation is dif-
ferent from the conclusions on MRI26. This clarifies the statement of Turner et al. who 
demonstrated that the surgeon’s assessment of complete surgical removal was unre-
lated to recurrence27. Specialization improves the outcome of pituitary surgery with less 
morbidity and mortality28. Differences in results among centres for pituitary surgery 
should be interpreted with caution even for those confined to comparable criteria of 
remission28. Nowadays minimal invasive neurosurgery i.c. endoscope assisted trans-
sphenoidal microsurgery is applied29.
Non-functioning pituitary adenomas are most frequently macroadenomas at 
diagnosis. In 90% of the cases, only a partial resection can be performed30. 
Concerning prolactinoma, surgery is only rarely performed, in case of resistance 
or intolerance to medication. 
In regard to acromegaly, 75% of the tumours are macroadenomas, which often 
extends laterally into the cavernous sinus or dorsally to the suprasellar region10. The 
cure rate with surgery alone for intrasellar lesions is 59-95%21,28 and for larger tumours 
26-68%21,28. Intraoperative GH-measurements and intraoperative MRI, can improve re-
sults31,32. 
For Cushing’s disease, the immediate postoperative cure rate after first surgery 
for microadenomas varies between 78-97% and for macroadenomas between 50-60%33. 
After curative resection, the recurrence percentage is 5-25%34.
Although small series have shown, that neurosurgery can improve pituitary hy-
pofunction11,35-38, more often deterioration of the pituitary function will occur30. Other 
specific side effects of surgery are leakage of cerebrospinal fluids, some degree of nasal 
discomfort and transient diabetes insipidus or mild SIADH (syndrome of inappropriate 
vasopressin secretion).
The mortality rate of neurosurgery is reported to vary between 0.26 and 3%39.
Radiation therapy
External beam radiation therapy for pituitary adenomas has been applied for more than 
100 years and the first results were reported by Beclere and Gramegna, two French physi-
cians in 190940.
Because of a high operative mortality in the early 20th century, radiation therapy 
was a primary method of treatment at that time. Surgery, however, was the only method 
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to restore vision. Gradually, it was discovered that surgery followed by radiation therapy 
was more effective than surgery alone41. In the sixties, there were differences in opi-
nion regarding the role of radiation therapy in NFA. Some investigators in the USA advo-
cated primary radiation therapy, but others recommended surgery followed by radiation 
therapy, promoted also by the British and Scandinavian schools. Nowadays, because of 
improved neurosurgical techniques, surgery is the treatment of choice in NFA with com-
pression. Primary radiation therapy is only applied if the patient refuses surgery or the 
general condition of the patient does not allow neurosurgery.
Immobilisation of the head of the patient to apply more precisely the radiation 
therapy to the tumour has been improved, starting with no immobilisation devices, fol-
lowed by tape and later on by immobilisation masks and stereotactic frames. 
Outlining the tumour for target volume definition in radiation therapy has been 
improved due to better imaging techniques. In the beginning, plain skull films, pneumo-
encephalography and later on cerebral angiography were used in outlining the tumour 
with its suprasellar and parasellar extension. Since the availability of CT-scans in the 
seventies this technique has been used for tumour outlining, followed by MRI 10 years 
later. Nowadays, MRI is the preferred modality - if applicable and available - for primary 
evaluation of the pituitary gland and outlining the tumour for radiation therapy co-
registered with the planning-CT scan42. 
Radiation therapy treatment schedules
Between 1930 and 1945 the general approach was to use multiple courses of low-dose 
radiation, repeated at intervals of 4 to 8 weeks. In general, a total of 3 to 5 courses were 
applied, guided by patient’s visual response. Daily doses of 200 rads were used to a total 
dose ranging from 2450 to 3000 rads per course.
Between 1945 and 1955, this policy changed into multiple courses of medium dose 
radiation (i.e. total dose of 30-40% more per course) and repeated with shorter intervals.
From 1955 the multiple course approach was abandoned because it was more dele-
terious for the normal tissues, due to the total accumulated dose of the different courses 
in a shorter overall treatment time. Since then, single-course high dose radiation therapy 
has generally been applied, intended to deliver a radiation dose sufficiently high to achieve 
permanent tumour control. The total dose increased in time from 2000 to 3000 rads in 2-3 
weeks, to 3500 to 4500 rads in 4 to 5 weeks. Occasionally, the total dose exceeded 5000 rads 
in 5-6 weeks, based on higher success rates (i.e. improved vision) with a higher dose. 
In 1953 the International Commission on Radiological Units and Measurements 
introduced the concept of absorbed dose and defined its unit, the rad. The rad was in 
use until the introduction after 1960 by Le Systeme Internationale (SI) of the SI unit for 
absorbed dose, called “Gray”, defined as J/kg. 100 rad is 1 J/kg is 1 Gray.
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In the sixties an initial slow build-up treatment with a small daily increment of 
25 to 50 cGray for the first three to four days was applied in order to minimize any radia-
tion-induced edema in the optic chiasm. Nowadays, we have abandoned the incremen-
tal dose in the first treatment week and the most frequently used schedules are 23 to 25 
fractions with a total dose of 45 to 50 Gray. Higher doses do not improve local control43.
Besides fractionation, the radiation source used also changed in time, based on 
technical improvements. In the period 1930 to 1940 200 kV photons were used, followed 
by 250 kV photons in the period 1940 to 1960. In 1955 the 25 MeV betatron came into use, 
followed in 1962 by the cobalt 60 machine. In 1966 the introduction of the linear accele-
rator was started, generating 6MV photons, still in use nowadays.
The irradiation techniques evolved in time as well; the older two lateral opposed 
field technique irradiated a large volume normal brain with an equivalent or even higher 
dose of what was applied to the tumour with reports of brain necrosis as a result of that. 
This technique was replaced by at least a three-field technique, consisting of 2 lateral 
fields and one vertex field, or a plan with multiple fields with wedges, following a bi-
coronal 1100 arc, better targeting the high dose to the tumour and reducing the high dose 
volume in the normal brain. Both coplanar techniques are still in use today44.
Since the availability of 3D radiation treatment planning systems in the nineties 
of the previous century, non-coplanar radiation techniques became possible. It became 
clear that for stereotactically guided conformal radiation therapy to volumes above 13 
ml, four to six non-coplanar fixed fields are clearly superior to coplanar field arrange-
ments, whereas even techniques approaching dynamic conformal radiation therapy 
such as a 30-field approach reveal no further sparing of normal brain tissue45. This tech-
nique has been introduced in the Radiation Oncology Department of the University 
Medical Center Groningen in 2001. 
Non-functioning pituitary adenoma
Most NFAs are incompletely resected, because they are inaccessible for complete resec-
tion for the neurosurgeon due to the critical structures in this area. In case of residual 
disease, it has been reported that immediate postoperative radiation therapy results in 
high local control rates of 90-95%13 and that an active surveillance policy results in a 
high local recurrence rate (50-80%) within 10 to 15 years27. The reason to postpone ra-
diation therapy in case of residual disease is that in most series ultimate local control 
rates with active surveillance policies, with salvage radiotherapy in case of regrowth, are 
similar to immediate postoperative radiation therapy. In addition, it has been assumed 
that delay of radiation therapy can prevent or delay hypopituitarism with its additional 
sequelae. One should be aware of the fact that the pituitary function is already affected 




For prolactinoma, reported cure rates after radiation therapy alone or in combination 
with surgery vary between 25% and 93% respectively34,44. Radiation therapy in prolacti-
noma patients is currently only rarely applied. 
GH-secreting pituitary adenoma
In acromegaly, radiation therapy can realize a reduction in GH excess of 30-50% in the 
first year, followed by 10-15% in the years thereafter. Despite the development of potent 
medical therapies and the improvement of neurosurgical techniques at least 10-20% of 
patients will need any form of radiation therapy. In addition to decreasing GH excess, 
radiation therapy has been shown to influence favourably the clinical consequences of 
the reduction in soft tissue excess, visual symptoms, headache and glucose intolerance, 
thereby confirming a favourable impact on the disease21.
ACTH-secreting pituitary adenoma
For Cushing’s disease reported cure rates after radiation therapy alone or in combina-
tion with surgery vary between 50% and 80% respectively34,44,46. 
Mortality and radiation therapy
Increased mortality due to radiation therapy is a subject for debate. It was already men-
tioned that in a large cohort of mainly non-functioning pituitary adenomas the overall 
age adjusted relative risk (RR) of death was 1.76 in comparison with the normal popula-
tion13. A possible risk factor, mentioned in this cohort for increased mortality, was radia-
tion therapy, but this factor showed no statistical significance. 
The Danish registry however reported no increased mortality due to cardiovas-
cular and cerebrovascular disease. In this study surgery type and radiation therapy were 
not identified as risk factors, while female sex was a risk factor8. Moreover, no increased 
mortality due to malignant disease was reported in all kinds of pituitary adenoma8.
Side-effects of radiation therapy
Acute side-effects
Acute side-effects due to fractionated radiation therapy are mild to moderate erythema, 
dry desquamation47,48, otitis externa47,49, otitis media47,49, tinnitus49, olfactory and gustatory 
changes49,50, temporary localized epilation at the beam entrance and exit depending on the 
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radiation dose47,50,51, headache49 and mild transient post radiation therapy somnolence52. In 
general, all these side-effects are minor, well tolerated and self-limiting in most patients50.
Late side-effects
Late side-effects or toxicity of the normal tissues due to radiation therapy will - as a 
general radiobiological rule – be smaller in fractionated radiation therapy. The risk of 
radiation-induced complications is expected to be rare with modern equipment, mod-
ern techniques and current recommended doses of 45 to 50 Gray in 1.8 Gray fractions in 
an overall treatment time of 5 weeks53. 
Hypopituitarism
In the past, the normal pituitary gland has been thought to be relatively radioresistant, 
tolerating doses up to 190 Gray without showing pathological damage. In time it became 
clear that radiation therapy can induce hypopituitarism54. It is the most prevalent late 
side effect as a result of direct damage to the pituitary and also secondary to hypotha-
lamic damage55, as is evidenced by appropriate pituitary responses to administration 
of exogenous hypothalamic releasing hormones56-58. There is some evidence to suggest 
that direct injury to hypothalamic neurones, rather than reduced cerebral blood flow, is 
the major cause of progressive hypothalamic-pituitary dysfunction after fractionated 
cranial irradiation. Direct damage to the cell nuclei in the hypothalamus may explain 
the delayed onset of hormone deficiency, because these cells are dividing slowly and die 
during mitosis years later before losing their function59. Radiation doses in excess of 50 
Gray can have a direct effect upon pituitary function. However, at doses below 50 Gray, 
hypopituitarism may initially be caused by hypothalamic dysfunction60. 
Radiation-induced hypopituitarism depends, besides on the total dose, on fraction 
size61. It increases in time for at least 10 years62. The severity, as measured by the number of 
anterior pituitary hormone deficiencies, depends on the total dose. Higher radiation dose 
given to the pituitary gland will result in a more rapid onset of hypopituitarism60. Among 
patients who developed multiple hormone deficiencies, the most frequent order of loss of 
anterior pituitary hormone function was GH, followed by LH/FSH, ACTH and then TSH.
Permanent radiation induced diabetes insipidus has not been reported 30,61. An 
explanation for the difference in radiosensitivity between the anterior and posterior 
pituitary lobe might be that the posterior lobe is only a storage place for hormones.
Pituitary function and pregnancy
In young adults with normal postoperative pituitary function and wish of future sib-
lings, some advocate not to give radiation therapy in order to avoid the possibility of 
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radiation-induced hypopituitarism, even if there is an increased risk on tumour recur-
rence with all its consequences63. Infertility due to hypopituitarism in men and women 
can be corrected with exogenous gonadotropins64,65.
Cerebrovascular disease (CVD)
A relationship between radiation therapy for pituitary adenoma and (as a consequence) 
CVD has not been found66. Cerebral infarctions manifested at intervals of 3.2-14.6 years 
after RT. Three out of seven patients with cerebral infarction had evidence of vascular 
disease outside the treatment field. Only age was a negative prognostic factor.
Out of 331 patients of The Royal Marsden cohort, 64 developed CVD after primary 
treatment of pituitary adenoma. In comparison with the normal population there was a 
relative risk of 4.1 (95% CI: 3.6-4.7%). The actuarial incidence of CVD after primary treatment 
of pituitary adenoma was 4% (95% CI: 2-7%) at 5 years, 11% (95% CI: 8-14%) at 10 years, and 
21% (95% CI: 16-28%) at 20 years measured from the date of radiation therapy. In this cohort, 
age, radiation therapy dose and extent of surgery were independent predictors for CVD. 
Erfurth et al. stated that radiation therapy might act as a risk factor for CVD, but 
not stronger than other risk factors for CVD in all types of pituitary patients67. Until this 
moment it is not clear if applied radiation therapy is a risk factor in relation to CVD 
afterwards.
Tumour induction
Tumour induction inside the brain
A cumulative risk of tumour induction inside the brain after surgery and radiation thera-
py of 1.3% (95%CI: 0.4-3.9%) to 2% (95%CI: 0.9-4.4%) over the first 10 years, and of 1.9% 
(95%CI: 0.7-5%) to 2.4% (95% CI: 1.2-5%) over the first 20 years has been reported68,69. The 
relative risk of a secondary brain tumour as compared to the incidence in the normal 
population is 9.4. The median time to detection is 7 years for glioma, 9.7 years for sar-
coma and 13.8 years for meningioma.
However, no firm support for an increased incidence of a second brain tumour 
is found by others in a cohort of 279 NFA patients treated between 1931 and 1988. Two 
astrocytomas – 7 and 24 years after irradiation - and one meningioma – 19 years after 
irradiation - were found (RR 2.7: 95%CI; 0.6-7.8) 70.
A genetic trait that predisposes to both pituitary tumours and brain tumours is 
an alternative causal factor. To support this idea, there are reports of the co-occurrence 
of meningioma and pituitary adenoma in non-irradiated patients71. Radiation-induced 




There is no evidence that cranial irradiation per se is the causal factor. A cohort 
study of non-irradiated pituitary tumour patients, who have the same initial malignan-
cy, is needed.
Tumour induction outside the brain
A relative risk for malignant tumours outside the brain of 3.91 is reported in patients 
with NFA in comparison with the general population73. The absolute incidence in the 
general population is estimated at 0.45%. In acromegalic patients the risk is not in-
creased in comparison with NFA patients73. However, no significant excess for cancer 
outside the brain is seen by others in pituitary patients in comparison with the general 
population69,74. The role of radiation therapy as risk factor is not yet clear and should be 
balanced with the probably already increased risk without radiation therapy.
Brain necrosis
The overall incidence of brain necrosis has been estimated at 0.2%75. This incidence will 
decline with modern equipment, such as stereotactic radiotherapy, and the currently 
recommended doses.
Radiation Optic Neuropathy (RON)
A prevalence of 0.53% for Radiation Optic Neuropathy in NFA has been reported76. The 
incidence will decline with modern radiation therapy equipment and current recom-
mended radiation therapy doses. An effective treatment for RON is not available76. 
Permanent radiation induced damage of the cranial nerves III, IV, V and VI has not 
been reported in series with modern radiation therapy equipment and currently recom-
mended radiation therapy doses.
Cognitive function
Patients with pituitary tumours may have impairment of both memory and executive 
function. No correlation has been found with tumour size and type77. The decrease in 
cognitive function seemed to be more pronounced among those treated with radiation 
therapy and mainly affected the executive function78. No short-term memory loss have 
been observed that is clearly attributed to radiation therapy50,79.
Research suggests that the pathogenesis of radiation induced neurocognitive 
deficit may involve radiation induced injury to proliferating neuronal progenitor cells 




One should be aware that others reported no cognitive impairment due to ra-
diation therapy in GH-deficient pituitary adenoma patients, not receiving GH-replace-
ment81.
Quality of Life
Patients with a pituitary adenoma in general have impairment in both physical and 
mental health measures compared with the normal population82. Patients with a non-
functioning adenoma however, have a greater impairment in measures of mental func-
tion than in physical function compared with the normal population and patients with 
other pituitary adenomas82.
Page et al. reported impaired quality of life among patients with non-functio-
ning pituitary adenoma who were irradiated, in comparison with those who were not 
irradiated. Patients were more depressed and emotionally affected. It remains unclear, 
whether these differences are direct effects of radiation therapy or indirect effects due 
to hormone abnormality or perception of disease severity83. The reasons why radiation 
therapy was applied were not mentioned in this paper and the differences found can be 
due to selection bias.
Nielsen et al. used the Short Form and Major depression inventory question-
naires8 to assess quality of life and depression among patients with non-functioning 
pituitary adenomas. In transsphenoidally operated patients, mental health scores were 
similar to the general population, while in patients that underwent craniotomy, mental 
health and mental component scores were lower. Radiation therapy, pituitary status or 
repeat surgery did not affect these quality of life dimensions. Age at first operation was 
an independent risk factor for reduced physical functioning. There was no influence of 
radiation therapy on depression.
Based on these results, it still remains unclear whether quality of life is nega-
tively affected by radiation therapy78.
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Aims of this thesis
The main objective of this thesis is to evaluate the results of radiation 
therapy among patients with pituitary adenomas with regard to treatment 
efficacy, side-effects and quality of life.
1 
To determine the role of radiation therapy in residual non-functioning pitu-
itary adenoma in relation to local control, side effects and overall survival, 
as reviewed in the literature and evaluated in our series. Chapter 2
2 
To evaluate the influence of radiation therapy on cognitive function and 
quality of life in patients with non-functioning pituitary adenoma. 
Chapter 3
3 
To establish the incidence of RON in acromegaly and its risk factors in the 
literature. This side-effect has been evaluated in irradiated acromegalic 
patients in the University Medical Center Groningen and is presented in a 
complete updated review. Chapter 4-5
4 
To establish the incidence of RON in non-functioning pituitary adenomas in 
the literature in addition to our own series, presented in the first available 
review published on this subject. Chapter 6
5 
To investigate the diagnostic role of new-imaging techniques: how are Posi-
tron Emission Tomography (PET) imaging characteristics affected by surgery 
and radiation therapy for pituitary adenoma. Chapter 7
6 
Finally, we investigated whether the position of head and neck cancer  
patients with conformal non-coplanar radiation techniques could be deter-
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